DPYD基因c.2766+3A>T变异导致外显子21跳跃并与DPD缺陷及严重氟尿嘧啶毒性相关
本文报告一名50岁男性结直肠癌患者接受辅助XELOX方案后出现危及生命的3-4级毒性,常规DPYD基因分型未见致病性变异,进一步外显子测序发现c.2766+3A>T等三个杂合变异,mRNA分析证实该内含子变异导致外显子21跳跃,患者表现为严重DPD缺陷,提示该变异应视为有害变异。
要点
- 常规DPYD基因分型阴性不能排除DPD缺陷,需考虑罕见内含子变异。
- c.2766+3A>T可导致外显子21跳跃,产生无功能DPD酶。
- 携带该变异者使用氟尿嘧啶类药物可能发生严重毒性。
核心结论
- c.2766+3A>T变异导致无功能DPD酶,是严重氟尿嘧啶相关毒性的可能原因,应被视为有害变异。
研究设计与样本
- 病例报告:一名50岁男性结直肠癌患者接受辅助XELOX方案后出现3-4级毒性,行DPYD基因分型、外显子测序及外周血单核细胞mRNA分析。
主要发现
- 常规DPYD基因分型未发现致病性变异,外显子测序检出c.1627A>G、c.2194G>A和c.2766+3A>T三个杂合变异。
- mRNA分析证实c.2766+3A>T导致外显子21跳跃,患者表现为严重DPD缺陷。
临床怎么用
- 对常规DPYD分型阴性但发生严重氟尿嘧啶毒性的患者,可考虑扩展测序检测罕见变异如c.2766+3A>T。
局限性
- 本文为单例病例报告,证据限于该患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fluoropyrimidines are widely used for the treatment of solid tumours, but they carry a significant risk of severe toxicity in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. CASE PRESENTATION: We describe a 50-year-old male with colorectal cancer who received adjuvant XELOX (oxaliplatin and capecitabine) and developed life-threatening grade 3-4 toxicities. Routine DPYD genotyping showed no pathogenic variants. Subsequent DPYD exon sequencing identified three heterozygous variants: c.1627A>G, c.2194G>A, and c.2766+3A>T. The latter, a rare intronic variant, was demonstrated to cause exon 21 skipping by mRNA analysis of peripheral blood mononuclear cells (PBMCs). The patient presented a profound DPD deficiency. CONCLUSION: The c.2766+3A>T variant leads to a non-functional DPD enzyme and is a likely cause of severe fluoropyrimidine-related toxicity. This variant should be considered deleterious.
引用
- Salvador-Martín S, Taladríz-Sender I, Zapata-Cobo P, et al. The variant c.2766+3A>T in DPYD leads to exon 21 skipping and is associated with DPD deficiency and severe fluoropyrimidine toxicity. Br J Clin Pharmacol. 2026. PMID: 42596594. doi:10.1002/bcp.70782
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。